2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

More documents

Recommendations

Info

Contact informationBekhtereva Str., 1192019 St. Petersburg, Russia+7 (812) 365 06 80institute@toxicology.ru | www.toxicology.ru60RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory
1.4.12 Smorodintsev Research Institute of InfluenzaCurrently, the Smorodintsev Research Institute of InfluenzaMinistry of Health of the Russian Federation is one of theleading research centers for solving key issues of virology,epidemiology, clinic and pathogenesis of viral infections,development of highly sensitive diagnostic medicines andeffective means of protecting the population from influenzaand other dangerous viral infections. The Federal Influenzaand ARI Center and the WHO National Influenza Centersuccessfully operate on the basis of the Institute as an integralpart of the system of global surveillance of infections. Themost important part of the scientific activity is the study of molecular-genetic andphylogenetic peculiarities of actual viruses. Research institute develops ways to predictdirections of variability of influenza viruses and other viral agents.Research institute conducts studies in order to identify genetic determinants ofpathogenicity of existing and emerging viruses, to predict the evolution of influenza viruses.The Institute has created a hardware and methodological infrastructure that allows toconduct a wide range of biochip studies, as well as to develop its own diagnostic methodsbased on protein and DNA biochips.On the basis of research institute methods of immune-enzyme analysis are being improved,new highly sensitive diagnostic test systems for influenza and other ARD viruses based onmonoclonal antibodies and rapid diagnostic preparations are being developed and produced.The Institute is developing and testing new influenza vaccines and has made progress in theirdesign and production technologies. The institute pays special attention to vaccine safety.Further research on recombinant influenza vaccine based on hybrid protein M2eHBc, a liveattenuated replication-deficient Fluvak influenza vaccine is promising and feasible.Employees of the Institute conduct research and directed synthesis of antiviral medicationsand develop new dosage forms.New scientific directions in medications development include the following:§ chemotherapeutic agents (Russian innovative projects);§ antiviral and antibacterial medications based on peptides and recombinant proteins.The research institute of influenza has a specialized clinic. The clinic provides consultativeand diagnostic assistance to patients, treats influenza and other acute respiratory infections,herpes infections, chronic hepatitis, and conducts clinical trials of new therapeutic andprophylactic medicines.RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory61
Page 2 and 3:
This publication was developed in t
Page 4 and 5:
1.5 Events ........................
Page 6 and 7:
2.42 PHARM-HOLDING ................
Page 8 and 9:
1 PART 1: MARKET RESEARCH1.1 Indust
Page 10 and 11: The Russian pharmaceutical market i
Page 12 and 13: Imported/localized drugs sales rati
Page 14 and 15: In 2020, the share of original drug
Page 16 and 17: 1.1.2 Commercial segment of the Rus
Page 18 and 19: 1.1.3 Drug reimbursement segmentAcc
Page 20 and 21: 1.1.4 Segment of purchases of drugs
Page 22 and 23: 1.1.5 Dietary supplements segmentAc
Page 24 and 25: The development of the innovative d
Page 26 and 27: Dynamics of pharmaceutical products
Page 28 and 29: § the term of the SPIC has been ex
Page 30 and 31: The Pharma-2030 Strategy elaboratio
Page 32 and 33: presence of viral RNA and antibodie
Page 34 and 35: § training system in the field of
Page 36 and 37: counter external risks (for example
Page 38 and 39: 1.3.2 The Pavlov First Saint Peters
Page 40 and 41: 1.3.3 North-Western State Medical U
Page 42 and 43: 1.3.4 Military Medical Academy name
Page 44 and 45: 1.3.6 Saint-Petersburg State Instit
Page 46 and 47: 1.3.7 Peter the Great St. Petersbur
Page 48 and 49: 1.3.9 Saint-Petersburg Medico-Socia
Page 50 and 51: 1.4.2 Almazov National Medical Rese
Page 52 and 53: 1.4.4 Institute of Cytology RASInst
Page 54 and 55: 1.4.6 Kashkin Research Institute of
Page 56 and 57: 1.4.8 Research Institute of Hygiene
Page 58 and 59: 1.4.10 Saint-Petersburg Pasteur Ins
Page 62 and 63: The Institute has Influenza and ARD
Page 64 and 65: 1.4.14 V. M. Gorbatov Federal Resea
Page 66 and 67: 1.5 Events1.5.1 Events calendarDate
Page 68 and 69: 1.5.2.2 Nordic Life Science DaysNor
Page 70 and 71: 1.5.2.4 HealthBIOThe HealthBIO even
Page 72 and 73: 1.5.2.6 BioJapanBioJapan has played
Page 74 and 75: 1.5.2.8 CPhI WorldwideCPhI is an es
Page 76 and 77: 1.5.2.10 INTERPHEX Japan 2021INTERP
Page 78 and 79: 1.5.3.2 IPhEB RussiaIPhEB Russia is
Page 80 and 81: 1.6 Clusters and associations1.6.1
Page 82 and 83: 1.6.3 Cluster of medical, environme
Page 84 and 85: 1.7 Cases and success stories1.7.1
Page 86 and 87: 1.8 Information sources1.8.1 Strate
Page 88 and 89: § DSM Group. Analytical report “
Page 90 and 91: 2.2 ALKOR BIOCompany profileThe St.
Page 92 and 93: 2.4 AMBERCompany profileAmber Group
Page 94 and 95: 2.6 AVENACompany profileAvena compa
Page 96 and 97: 2.8 BELKOZINCompany profileBelkozin
Page 98 and 99: 2.10 BIOCADCompany profileBiocad is
Page 100 and 101: 2.12 BIOPHARMOSCompany profileBioPh
Page 102 and 103: 2.14 BIOTECHCompany profileBiotech
Page 104 and 105: 2.16 CYTOMEDCompany profileCytomed
Page 106 and 107: 2.18 EKVUSCompany profile“Ekvus
Page 108 and 109: 2.20 FARMAKOGENCompany profileFarma
Page 110 and 111:
2.22 FRAMEBIOTEKCompany profileFram
Page 112 and 113:
2.24 GEROPHARMCompany profileGeroph
Page 114 and 115:
2.26 GROTEXCompany profileSolopharm
Page 116 and 117:
2.28 HARMSCompany profileHistory of
Page 118 and 119:
2.30 LEKKERCompany profileThe histo
Page 120 and 121:
2.32 NEPHRONCompany profileResearch
Page 122 and 123:
2.34 NIKACompany profileNika Factor
Page 124 and 125:
2.36 PHARM. ASSOCIATION NAMED FOR P
Page 126 and 127:
2.38 PHARMA VAMCompany profilePharm
Page 128 and 129:
2.40 PHARMAKOR PRODUCTIONCompany pr
Page 130 and 131:
2.42 PHARM-HOLDINGCompany profilePh
Page 132 and 133:
2.44 PHARMSYNTHEZCompany profilePha
Page 134 and 135:
2.46 PPDPCompany profileEnterprise
Page 136 and 137:
2.48 RESEARCH INSTITUTE OF INNOVATI
Page 138 and 139:
2.50 SEVERNAIA ZVEZDACompany profil
Page 140 and 141:
2.52 VITAL DEVELOPMENT CORPORATIONC
Page 142 and 143:
For notes142RUSSIAN-FINNISH LIFE SC
Page 144:
144RUSSIAN-FINNISH LIFE SCIENCE IND
show all

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Create successful ePaper yourself

Delete template?

Save as template?